

Nycomed Amersham plc

[View the current Nycomed Amersham plc Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/7739-Nycomed+Amersham+plc.html)

(<http://www.bioportfolio.com/bi corporate/7739-Nycomed+Amersham+plc.html>)

Contact Details:

Amersham Place

Tel: +44 (0) 1494-544000

Little Chalfont

Fax: +44 (0) 1494-542266

Buckinghamshire

Email:

HP7 9NA

United Kingdom

Amersham plc is a world leader in medical diagnostics and in life sciences, delivering pharmaceutical products for the diagnosis and treatment of disease and technologies for biotechnology research and drug discovery. Headquartered in the UK, the company has annual sales of £1.4 billion (US\$ 2.1 billion) and 9,000 employees worldwide.

Recent Publications by Nycomed Amersham plc:



- [Effects of topiramate on kainate- and domoate-activated \[14C\]guanidinium ion flux through GluR6 channels in transfected BHK cells using Cytostar-T scintillating microplates.](#)
*PURPOSE: This study was undertaken to test the hypothesis that topiramate...*29th April, 2000
Nycomed Amersham plc, Cardiff, United Kingdom.- *Epilepsia*. 2000;41 Suppl 1:S48-51.
- [Biologic mechanisms of 89SrCl2 incorporation into type I collagen during bone mineralization.](#)
*89SrCl2 is currently used as a palliative treatment for painful osseous...*26th February, 2000
Nycomed Amersham plc, Imaging Research and Development, Amersham- *J Nucl Med*. 2000 Jan;41(1):183-8.

Press Releases on Nycomed Amersham plc:

Victory Pharma, Inc. Announces Launch of NAPRELAN(R) Dose Card	23rd November, 2009	Victory Pharma, Inc.	SAN DIEGO, Nov. 23 /PRNewswire/ -- Victory Pharma, Inc. ("Victory") announced today the launch of NAPRELAN® Dose Card, a further extension of Victory's NAPRELAN franchise. NAPRELAN
Inimex Announces Appointment of New CEO	23rd November, 2009	Inimex Pharmaceuticals Inc.	BURNABY, BC, Nov. 23 /PRNewswire/ - Inimex Pharmaceuticals, Inc. announced today that it has appointed Michael J. Abrams, Ph.D as its President and CEO. Abrams brings more than 25 years of drug
Reportlinker Adds Imaging Agents - A Worldwide Market Review	20th November, 2009	Reportlinker	NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Imaging Agents - A Worldwide Market Review
Reportlinker Adds Pulmonary Drug Delivery Technologies - A Global Market Perspective	18th November, 2009	Reportlinker	NEW YORK, Nov. 18 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Pulmonary Drug Delivery Technologies - A Global Market Perspective http://
Reportlinker Adds Anticoagulants - A Global Market Review	18th November, 2009	Reportlinker	NEW YORK, Nov. 18 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Anticoagulants - A Global Market Review http://www.reportlinker.com

Nycomed Amersham plc Patents:



- 6653299- [Labelled factor XIIIa substrates](#)
- 5922301- [Radiolabelled amino acid formulations stored in an unfrozen state](#)
- 5932707- [Thioether-containing metal chelating compounds](#)
- 6001979- [Cores for technetium radiopharmaceuticals](#)
- 6004531- [Metal chelating compounds having an SNNN donor set](#)
- 6124440- [Cores for technetium radiopharmaceuticals](#)

- 6132359- [Brachytherapy seeds](#)
- 6132698- [Radiolabelled compound formulations containing a dye](#)
- 6153775- [Polydentate imines and their metal complexes](#)
- 6329513- [Cores for technetium radiopharmaceuticals](#)
- 6348599- [Cyanine dyes](#)
- 6360183- [Device and method for triggering a random event](#)
- 6444682- [Base analogues](#)
- 6458966- [Dye intermediate and method](#)
- 6605611- [Base analogues](#)
- 5874811- [Superconducting cyclotron for use in the production of heavy isotopes](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:Peter.Barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

